H.R. 1262 · 119th Congress · Health

Mikaela Naylon Give Kids a Chance Act

Expands FDA authority for pediatric disease research and reauthorizes pediatric research funding through 2027. AI-read

Passed House4.6k words Introduced Feb 12, 2025 · Latest action Dec 2, 2025

How far it has goneStage 4 of 6
  1. IntroducedFeb 12, 2025 Done
  2. CommitteeReported Oct 31, 2025 Done
  3. House floorPassed by voice vote · Dec 1, 2025 Done
  4. Senate floorAwaiting vote Current stage
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.

Specifically, the bill

• modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;

• permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;

• renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and

• reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.

The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra, a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Congressional Research Service · summary of “Introduced in House” version · Feb 12, 2025

Who lobbies on it

20 organizations, more than 99% of House bills · 105 filings · Q1 2025–Q3 2026

These 20 organizations’ PACs gave $1.4M to 166 of the 314 members sponsoring or cosponsoring H.R. 1262 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Ptc Therapeutics, Inc. 7 of 7 quarters
    “…H.R.1262/S.932 - Give Kids a Chance Act of 2025.”

    $730K lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Healthcare Institute of New Jersey 7 of 7 quarters
    “…Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule…”

    $148K lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Pharmaceutical Research and Manufacturers of America 6 of 7 quarters
    “…H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act…”

    $26.6M lobbying spend in 2026 to date, all issuesQ2 2026 filing

17 more organizations, every filingPROUpgrade

Organizations that named H.R. 1262 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

13 actions · newest first
  1. Dec 2, 2025Received in the Senate.
  2. Dec 1, 2025Motion to reconsider laid on the table Agreed to without objection.
  3. Dec 1, 2025On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
  4. Dec 1, 2025Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
Show all 13 actionsShow fewer
  1. Dec 1, 2025DEBATE - The House proceeded with forty minutes of debate on H.R. 1262.
  2. Dec 1, 2025Considered under suspension of the rules. (consideration: CR H4929-4935)
  3. Dec 1, 2025Mr. Carter (GA) moved to suspend the rules and pass the bill, as amended.
  4. Oct 31, 2025Placed on the Union Calendar, Calendar No. 304.
  5. Oct 31, 2025Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-352.
  6. Sep 17, 2025Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 47 - 0.
  7. Sep 17, 2025Committee Consideration and Mark-up Session Held
  8. Feb 12, 2025Referred to the House Committee on Energy and Commerce.
  9. Feb 12, 2025Introduced in House

What members said about it

  • Statement · Press release · Dec 3, 2025 · Bresnahan R-PA

    Bresnahan Reaffirms Commitment to Improving Healthcare for NEPA

    Today, Rep. Rob Bresnahan, Jr. (PA-08) announced his support 50 healthcare bills directly in response to the specific needs and challenges brought forward by families across Northeastern Pennsylvania.

    “Over my first 11 months in Congress, families across NEPA have shared their struggles and their hopes for better access to care, lower costs, and stronger treatments and research. I promised them I would never stop fighting to improve the health and wellbeing of our communities, especially our most vulnerable.”
  • Statement · Press release · Dec 3, 2025 · Harshbarger R-TN

    Harshbarger Applauds House Passage of Her Medical Supply Chain Security Provision in Rep. McCaul’s Give Kids A Chance Act

    Congresswoman Diana Harshbarger (R-TN) applauded the House’s unanimous passage of H.R. 1262, the Mikaela Naylon Give Kids A Chance Act led by Representative Michael McCaul (R-TX), which includes her bipartisan provision to strengthen and…

    “I am proud the House passed this bipartisan bill led by my colleague Congressman McCaul that included my provision to establish an FDA office in the Abraham Accords region and begin shifting critical medical supply chains to trusted allies.”
  • Statement · Press release · Dec 1, 2025 · Carter R-GA

    WATCH: Carter supports research and development to improve outcomes for children with rare diseases

    Rep. Earl L. “Buddy” Carter (R-GA) today spoke on the House floor in favor of H.R. 1262, the Mikaela Naylon Give Kids a Chance Act, which boasts bipartisan support and invests in research and development of cures and treatments for children…

    “Mr. Speaker, I encourage my colleagues to support this bill.”